Main Inclusion Criteria:

          1. Male or female patient ≥ 18 years of age

          2. Histologically or cytologically confirmed non-squamous NSCLC

          3. EGFR-mutation positive patients must have progressed on or had intolerance to an EGFR
             small molecule tyrosine kinase inhibitor

          4. Patients whose tumors harbor an anaplastic lymphoma kinase (ALK) translocation must
             have progressed on or had intolerance to an ALK inhibitor;

          5. No prior adjuvant chemotherapy within 1 year of the first treatment day if there is
             recurrent disease

          6. At least 1 site of measurable disease per Response Evaluation Criteria in Solid Tumors
             (RECIST) v1.1

          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and minimum
             life expectancy of ≥ 3 months

          8. Adequate bone marrow, renal and liver function

        Main Exclusion Criteria:

          1. Histologic evidence of predominantly squamous cell NSCLC

          2. Brain metastasis and/or leptomeningeal disease (known or suspected)

          3. Peripheral neuropathy > CTCAE grade 1

          4. Possibility of a curative local treatment (surgery and/or radiotherapy)

          5. Previous chemotherapy except adjuvant treatment with progression of disease documented
             ≥ 12 months after end of adjuvant treatment

          6. Having received treatment in another clinical study within the 30 days prior to
             commencing study treatment or having side effects of a prior study drug that are not
             recovered to grade ≤ 1 or baseline, except for alopecia

          7. Concurrent chronic systemic immunotherapy, chemotherapy or hormone therapy